Evidence map›Paper›PMID 37478826›Full record

ArticleCell chemical biology2023

Catalytic spike antibodies: A new paradigm in neutralization.

Ryan P McNamara

Open access · greenAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell chemical biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Ryan P McNamaraRagon Institute of Mass General, MIT, and Harvard, 400 Technology Square, Cambridge, MA 02139, USA. Electronic address: rpmcnamara@mgh.harvard.edu.
Massachusetts General Hospital · US

Funding

Technology CoreU19AI135995 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI Kristian Graugaard Andersen · 2018 to 2026
$32.0M
Demystifying the antiviral activity of the IgG3+ antibody responseR37AI080289 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI ALTER, GALIT · 2015 to 2022
$5.8M
ChimeraX -- Next Generation Visualization and Analysis Software for Multiscale ModelingR01GM129325 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FERRIN, THOMAS E · 2018 to 2025
$5.2M
Immunologic Signatures of SARS-CoV-2 Vaccination and DiseaseU01CA260476 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H. · 2020 to 2024
$3.7M
CHLAMYDIA PNEUMONIAE AND MACROPHAGES IN ATHEROSCLEROSISR01AI042790 · NIAID · UNIVERSITY OF WISCONSIN MADISON · PI BYRNE, GERALD IRWIN · 1999 to 2003
$983k
NCI NIH HHS U01 CA260476NIAID NIH HHS R01 AI042790NIAID NIH HHS R37 AI080289NIAID NIH HHS U19 AI135995NIGMS NIH HHS R01 GM129325
6 · The paper itself

Abstract

In this issue, McConnell et al.

Indexed as

Antibodies, CatalyticCOVID-19AntibodiesAntibodies, NeutralizingCOVID-19 SerotherapyHumansSARS-CoV-2AntibodiesAntibodies, CatalyticAntibodies, Neutralizing

Identifiers

PMID37478826
PMCPMC11339862
OpenAlexW4384938565

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.